缬沙坦治疗慢性心力衰竭的临床疗效

Effect of Valsartan on chronic heart failure

目的观察缬沙坦治疗慢性心力衰竭的临床疗效。方法心力衰竭患者58例,随机分为两组:即缬沙坦治疗组30例服用缬沙坦80 mg/d;常规治疗组28例未服用缬沙坦及其他血管紧张素Ⅱ-1型受体拮抗剂。缬沙坦组和常规治疗组均于治疗前,治疗后半年分别行心脏彩色多普勒检查。结果两组在治疗前及治疗后对比,缬沙坦组比常规治疗组左心室舒张末期容积(LVEDV)[(102.6±25.6)mlvs.(117.2±28.5)ml,P<0.05]及左心室收缩末期容积(LVESV)[(53.1±20.6)mlvs.(66.4±28.7)ml,P<0.05]明显减小,而左室射血分数(LVEF)明显提高[(56.1±9.6)%vs.(47.4±13.2)%,P<0.01]。随访1年,结果缬沙坦组(24.0%)比常规治疗组(46.7%)心力衰竭再发生率降低有统计学意义(P<0.05)。结论应用缬沙坦治疗心力衰竭,患者心功能有明显的改善。

Objective To observe the effect of valsartan on chronic heart failure. Methods Fifty-eight chronic heart failure patients were randomly divided into two groups： 30 patients treated with Valsartan （Valsartan group） and 28 patients received stardard therapies plus without Valsartan or any other angiotensin Ⅱ type 1 receptor blockade （control group）. Both groups underwent echocardiography before and 6 months after treatment. Results In Valsartan group, left ventricular end-diastolic volume （LVEDV） [ （ 102.6 ± 25.6 ） ml vs. （ 117.2 ± 28.5） ml, P〈 0.05]and left ventricular end-systolic volume（LVESV） [（53.1±20.6）ml vs. （66.4±28.7）ml, P〈0.05] were significantly decreased after treatment while left ventricular ejection fraction（LVEF） [（56. 1±9. 6）% us. （ 47.4±13. 2）%, P〈0.01] was significantly increased. After one year＇s follow up, the rate of recurrent heart failure in Valsartan group was significantly lower than in control group （24.0% vs. 46.7%, P〈0.05）. Conclusions Valsartan can prevent ventriclular remolding and decrease recurrent heart failure.